Ramatroban

Ramatroban

Systematic (IUPAC) name
3-((3R)-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic acid
Clinical data
Legal status	℞ (Prescription only)
Routes of administration	Oral
Identifiers
CAS Number	116649-85-5
ATC code	none
PubChem	CID: 123879
IUPHAR/BPS	1910
ChemSpider	110413
UNII	P1ALI72U6C Y
ChEMBL	CHEMBL361812
Chemical data
Formula	C21H21FN2O4S
Molecular mass	416.46 g/mol
SMILES C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
InChI InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1 Key:LDXDSHIEDAPSSA-OAHLLOKOSA-N

Ramatroban (INN) is a thromboxane receptor antagonist.

It is also a DP₂ receptor antagonist.

It is indicated for the treatment of coronary artery disease. It has also been used for the treatment of asthma.

It was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer and Nippon Shinyaku Co. Ltd. under the tradename Baynas.

External links

• (Japanese) Baynas